Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Dow
Cantor Fitzgerald
Argus Health
McKesson
Johnson and Johnson
Queensland Health
Cerilliant
Fuji

Generated: October 23, 2017

DrugPatentWatch Database Preview

ADEMPAS Drug Profile

« Back to Dashboard

What is the patent landscape for Adempas, and what generic Adempas alternatives are available?

Adempas is a drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this drug.

This drug has seventy-eight patent family members in forty-three countries and fourteen supplementary protection certificates in twelve countries.

The generic ingredient in ADEMPAS is riociguat. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the riociguat profile page.

Summary for Tradename: ADEMPAS

US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list42
Clinical Trials: see list8
Patent Applications: see list62
Drug Prices:see details
DailyMed Link:ADEMPAS at DailyMed

Pharmacology for Tradename: ADEMPAS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare
ADEMPAS
riociguat
TABLET;ORAL204819-001Oct 8, 2013RXYesNo► Subscribe► SubscribeYY ► Subscribe
Bayer Hlthcare
ADEMPAS
riociguat
TABLET;ORAL204819-005Oct 8, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Bayer Hlthcare
ADEMPAS
riociguat
TABLET;ORAL204819-002Oct 8, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Bayer Hlthcare
ADEMPAS
riociguat
TABLET;ORAL204819-001Oct 8, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Bayer Hlthcare
ADEMPAS
riociguat
TABLET;ORAL204819-003Oct 8, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Bayer Hlthcare
ADEMPAS
riociguat
TABLET;ORAL204819-005Oct 8, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Bayer Hlthcare
ADEMPAS
riociguat
TABLET;ORAL204819-002Oct 8, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Bayer Hlthcare
ADEMPAS
riociguat
TABLET;ORAL204819-005Oct 8, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Bayer Hlthcare
ADEMPAS
riociguat
TABLET;ORAL204819-004Oct 8, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Bayer Hlthcare
ADEMPAS
riociguat
TABLET;ORAL204819-004Oct 8, 2013RXYesNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ADEMPAS

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)0006569► Subscribe
Germany19834044► Subscribe
China1317005► Subscribe
Norway319073► Subscribe
Slovenia1506193► Subscribe
Russian Federation2232161► Subscribe
Poland214985► Subscribe
Brazil0309855► Subscribe
Portugal1506193► Subscribe
South Africa200100222► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ADEMPAS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0032France► SubscribePRODUCT NAME: RIOCIGUAT,SES SELS,SES ISOMERES ET SES HYDRATES.; REGISTRATION NO/DATE: EU/1/13/907/001-015 20140327
00659Netherlands► SubscribePRODUCT NAME: RIOCIGUAT, DESGEW ENST IN DE; REGISTRATION NO/DATE: EU/1/13/907 20140327
14/028Ireland► SubscribePRODUCT NAME: RIOCIGUAT OR A SALT, ISOMER OR HYDRATE THEREOF; REGISTRATION NO/DATE: EU/1/13/907/001-015 20140327
0140015 00109Estonia► SubscribePRODUCT NAME: RIOTSIGUAAT;REG NO/DATE: K(2014)2152 (LOPLIK) 31.03.2014
419Luxembourg► SubscribePRODUCT NAME: RIOCIGUAT ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES(ADEMPAS)
/2014Austria► SubscribePRODUCT NAME: RIOCIGUAT; REGISTRATION NO/DATE: EU/1/13/907 20140331
2014018Lithuania► SubscribePRODUCT NAME: ; REGISTRATION NO/DATE: EU/1/13/907/001 - EU/1/13/907/015 20140327
400019Hungary► SubscribePRODUCT NAME: RIOCIGUAT; REG. NO/DATE: EU/1/13/97 20140327
2014018,C1506193Lithuania► SubscribePRODUCT NAME: RIOCIGUATUM; REGISTRATION NO/DATE: EU/1/13/907/001 - EU/1/13/907/015 20140327
0659Netherlands► SubscribePRODUCT NAME: RIOCIGUAT, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF HYDRAAT; REGISTRATION NO/DATE: EU/1/13/907 20140331
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Novartis
AstraZeneca
Medtronic
Express Scripts
Chubb
Citi
Teva
Farmers Insurance
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot